Two Indexes.
Two Distinct Biotech Exposures.

LifeSci Index Partners provides rules-based, science-first indexes covering the full biotechnology drug development lifecycle.

Explore Our Indexes →

Our Indexes

Two complementary lenses on the biotechnology sector — from FDA-approved commercial stage to clinical-stage pipeline innovation.

LSCIBP

LifeSci Biotechnology Products Index

Commercial-Stage Biotech

Tracks U.S.-listed pure biotech companies with at least one FDA-approved drug therapy. 63 components. Equal weight. Semi-annual reconstitution.

63 Components $4.3B Median Mkt Cap Equal Weight
LSCIBC

LifeSci Biotechnology Clinical Trials Index

Clinical-Stage Biotech

Tracks U.S.-listed pure biotech companies with a lead drug in Phase 1, 2, or 3 clinical trials. 126 components. Equal weight. Semi-annual reconstitution.

126 Components $1.4B Median Mkt Cap Equal Weight

Why Biotech Now

Three structural forces are reshaping biotechnology investment.

🧬The Silver Tsunami

Aging demographics across developed economies are driving unprecedented healthcare demand. By 2030, all Baby Boomers will be over 65 — accelerating the need for novel therapies across oncology, neurology, and rare disease.

📊The Patent Cliff

$236B+ in branded pharmaceutical revenue is at risk through 2030 as key patents expire, forcing Big Pharma to acquire biotech innovation to replenish their pipelines. M&A premiums for clinical and commercial-stage biotechs remain elevated.

🔬The Science Revolution

Biotechnology now accounts for over 70% of FDA novel drug approvals. Breakthroughs in gene therapy, mRNA platforms, and AI-accelerated drug discovery are compressing development timelines and expanding the addressable market.

What Leaders Are Saying

“I’m positive on biotech… my instinct is we’re about to cure a lot of diseases.”
Dario Amodei, CEO Anthropic (MD/PhD)
People by WTF Podcast, February 2026
“My confidence is so high… we now have visibility to over $70 billion of potential commercial opportunity by the mid-2030s.”
Robert Davis, Chairman & CEO Merck
J.P. Morgan Healthcare Conference, January 2026

Annual Returns (2016–2025)

Calendar-year total return for each LifeSci index.

Past performance is not indicative of future results. One cannot invest directly in an index. Source: LifeSci Index Partners / Indxx, Inc.

Ready to explore biotech indexing?

Learn how our rules-based methodology captures the full drug development lifecycle.

View Methodology →